Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non‐small‐cell lung cancer-Reference-Cited by-同舟云学术

Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non‐small‐cell lung cancer

Published:2014-12 Issue:12 Volume:105 Page:1584-1590
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Gemma Akihiko¹,Kudoh Shoji²,Ando Masahiko³,Ohe Yuichiro⁴,Nakagawa Kazuhiko⁵,Johkoh Takeshi⁶,Yamazaki Naoya⁷,Arakawa Hiroaki⁸,Inoue Yoshikazu⁹,Ebina Masahito¹⁰,Kusumoto Masahiko¹¹,Kuwano Kazuyoshi¹²,Sakai Fumikazu¹³,Taniguchi Hiroyuki¹⁴,Fukuda Yuh¹⁵,Seki Akihiro¹⁶,Ishii Tadashi¹⁶,Fukuoka Masahiro¹⁷

Affiliation:

1. Department of Pulmonary Medicine and Oncology Nippon Medical School Graduate School of Medicine TokyoJapan

2. Anti‐Tuberculosis Association Double‐Barred Cross Hospital TokyoJapan

3. Center for Advanced Medicine and Clinical Research Nagoya University Graduate School of Medicine NagoyaJapan

4. Department of Respiratory Medicine National Cancer Center Hospital TokyoJapan

5. Department of Medical Oncology Kinki University School of Medicine OsakaJapan

6. Department of Radiology Kinki Central Hospital of Mutual Aid Association of Public School Teachers HyogoJapan

7. Department of Dermatology National Cancer Center Hospital TokyoJapan

8. Department of Radiology Dokkyo Medical University Hospital TochigiJapan

9. Clinical Research Center National Hospital Organization Kinki‐Chuo Chest Medical Center OsakaJapan

10. Pulmonary Center Tohoku Pharmaceutical University Hospital SendaiJapan

11. Department of Diagnostic Radiology National Cancer Center Hospital East ChibaJapan

12. Division of Respiratory Medicine Department of Internal Medicine Jikei University School of Medicine TokyoJapan

13. Department of Diagnostic Radiology Saitama Medical University International Medical Center SaitamaJapan

14. Department of Respiratory Medicine and Allergy Tosei General Hospital AichiJapan

15. Division of Diagnostic Pathology Itabashi Chuo Medical Center TokyoJapan

16. Department of Pharmacovigilance Chugai Pharmaceutical Co. Ltd TokyoJapan

17. Izumi Municipal Hospital Osaka Japan

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.12550

Reference13 articles.

1. Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

2. Efficacy and Safety of Erlotinib Monotherapy for Japanese Patients with Advanced Non-small Cell Lung Cancer: A Phase II Study

3. Phase II study of erlotinib in Japanese patients with advanced non‐small cell lung cancer;Takahashi T;Anticancer Res,2010

4. Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors

5. The results of gefitinib prospective investigation;Yoshida S;Med Drug J,2005

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The radiologist’s role in detecting systemic anticancer therapy-related interstitial lung disease: an educational review;Insights into Imaging;2024-08-01

2. The incidence of drug-induced interstitial lung disease caused by epidermal growth factor receptor tyrosine kinase inhibitors or immune checkpoint inhibitors in patients with non-small cell lung cancer in presence and absence of vascular endothelial growth factor inhibitors: a systematic review;Frontiers in Oncology;2024-06-11

3. Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101);Targeted Oncology;2024-04-13

4. Successful rechallenge twice with different EGFR-TKIs in a patient with lung adenocarcinoma after EGFR- TKI-induced grade 3 stomatitis and interstitial lung disease: a case report;2024-04-03

5. Drug-induced interstitial lung disease: a narrative review of a clinical conundrum;Expert Review of Respiratory Medicine;2024-02